Invasive intraductal oncocytic papillary neoplasms (IOPN) and adenocarcimoma arising from intraductal papillary mucinous neoplasms (A-IPMN) of the pancreas: comparative analysis of clinicopathological features, patterns of recurrence and survival: a multicentre study.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Lucocq, JamesHaugk, Beate
Joseph, Nejo
Hawkyard, Jake
White, Steve
Mownah, Omar
Menon, Krishna
Furukawa, Takaki
Inoue, Yosuke
Hirose, Yuki
Sasahira, Naoki
Mittal, Anubhav
Samra, Jas
Sheen, Amy
Feretis, Michael
Balakrishnan, Anita
Ceresa, Carlo
Davidson, Brian
Pande, Rupaly
Dasari, Bobby V M
Tanno, Lulu
Karavias, Dimitrios
Helliwell, Jack
Young, Alistair
Nunes, Quentin
Urbonas, Tomas
Silva, Michael
Gordon-Weeks, Alex
Barrie, Jenifer
Gomez, Dhanny
van Laarhoven, Stijn
Nawara, Hossam
Doyle, Joseph
Bhogal, Ricky
Harrison, Ewen
Roalso, Marcus
Zaharia, Claudia
Ciprani, Debora
Aroori, Somaiah
Ratnayake, Bathiya
Koea, Jonathan
Capurso, Gabriele
Bellotti, Ruben
Stättner, Stefan
Alsaoudi, Tareq
Bhardwaj, Neil
Jeffery, Fraser
Connor, Saxon
Cameron, Andrew
Jamieson, Nigel
Roberts, Keith
Soreide, Kjetil
Gill, Anthony J
Pandanaboyana, Sanjay
Publication date
2024-07-20
Metadata
Show full item recordAbstract
Background: Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas are now considered a separate entity to intraductal papillary mucinous neoplasms (IPMN). Invasive IOPNs are extremely rare, and their recurrence patterns, response to adjuvant chemotherapy and long-term survival outcomes are unknown. Methods: Consecutive patients undergoing pancreatic resection (2010-2020) for invasive IOPNs or adenocarcinoma arising from IPMN (A-IPMN) from 18 academic pancreatic centers worldwide were included. Outcomes of invasive IOPNs were compared with A-IPMN invasive subtypes (ductal and colloid A-IPMN). Results: 415 patients were included: 20 invasive IOPN, 331 ductal A-IPMN and 64 colloid A-IPMN. After a median follow-up of 6-years, 45% and 60% of invasive IOPNs had developed recurrence and died, respectively. There was no significant difference in recurrence or overall survival between invasive IOPN and ductal A-IPMN. Overall survival of invasive IOPNs was inferior to colloid A-IPMNs (median time of survival 24.4 months vs. 86.7, months, p = 0.013), but the difference in recurrence only showed borderline significance (median time to recurrence, 22.5 months vs. 78.5 months, p = 0.132). Adjuvant chemotherapy, after accounting for high-risk features, did not reduce rates of recurrence in invasive IOPN (p = 0.443), ductal carcinoma (p = 0.192) or colloid carcinoma (p = 0.574). Conclusions: Invasive IOPNs should be considered an aggressive cancer with a recurrence rate and prognosis consistent with ductal type A-IPMN.Citation
Lucocq J, Haugk B, Joseph N, Hawkyard J, White S, Mownah O, Menon K, Furukawa T, Inoue Y, Hirose Y, Sasahira N, Mittal A, Samra J, Sheen A, Feretis M, Balakrishnan A, Ceresa C, Davidson B, Pande R, Dasari BVM, Tanno L, Karavias D, Helliwell J, Young A, Nunes Q, Urbonas T, Silva M, Gordon-Weeks A, Barrie J, Gomez D, van Laarhoven S, Nawara H, Doyle J, Bhogal R, Harrison E, Roalso M, Zaharia C, Ciprani D, Aroori S, Ratnayake B, Koea J, Capurso G, Bellotti R, Stättner S, Alsaoudi T, Bhardwaj N, Jeffery F, Connor S, Cameron A, Jamieson N, Roberts K, Soreide K, Gill AJ, Pandanaboyana S. Invasive intraductal oncocytic papillary neoplasms (IOPN) and adenocarcimoma arising from intraductal papillary mucinous neoplasms (A-IPMN) of the pancreas: comparative analysis of clinicopathological features, patterns of recurrence and survival: a multicentre study. HPB (Oxford). 2024 Jul 20:S1365-182X(24)02222-6. doi: 10.1016/j.hpb.2024.07.410. Epub ahead of print. PMID: 39084948.Type
ArticlePMID
39084948Journal
HPBPublisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.hpb.2024.07.410